NCT03523390: Phase I/Ib Multiple Ascending Dose Study in China

NCT03523390
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with active progressing brain metastases that require treatment
https://ClinicalTrials.gov/show/NCT03523390

Comments are closed.

Up ↑